PubMed Trending Research Digest — June 06, 2026

Automated digest · 98 articles · 15 research areas · June 06, 2026

Overview

This week’s digest is dominated by a convergence of precision risk stratification and mechanism-driven therapy across cardiometabolic disease, cancer, and neurobiology. On the cardiovascular/metabolic side, multiple studies emphasize lipid biology beyond traditional LDL-C—using accessible indices (e.g., TyG and non-HDL/HDL-related metrics) and particle-centric concepts (ApoB, Lp(a) residual risk) to better forecast incident disease and residual risk. In parallel, mechanistic vascular work highlights how specific metabolic pathways (e.g., ACADM-dependent β-oxidation) and immune–metabolic checkpoints (e.g., CD47–SIRPα barriers coupled to efferocytosis metabolism) can shape atherosclerosis progression and stability.

In oncology and immunology, the theme is “microenvironment-aware” immunotherapy and refined biomarkers. Several studies use multi-omics/proteogenomics to define prognostic strata (HBV-HCC subtypes, DLBCL proteogenotypes, lung cancer risk protein signatures) and to map how tumor or host states influence response (hypoxia-driven TAM programs in ccRCC; microglial state divergence at the Aβ–tau inflection point; innate immune clonal dynamics in tumors). Therapeutic advances range from next-generation CAR T strategies and combination approaches to overcome resistance (e.g., TLR7/8 agonist integration for medulloblastoma CAR T durability; epigenetic sensitization to CD47 blockade in TNBC) to longer-term follow-up and regimen comparisons in lung cancer and other settings.

Finally, neuro- and immune-mechanistic studies underscore how aging, inflammation, and cellular state transitions can be both measured and targeted. Work on microglial biology (including human lineage dynamics and metabolic coupling that supports synaptic plasticity) pairs with reviews on senescence-driven neurodegeneration, while stroke-focused interventions explore both cell-free EV strategies and neuroprosthetic stimulation. Across infectious disease and innate immunity, studies dissect how host defense modules (protease–MBL, ISG translation blockade, xenophagy pathways) and pathogen condensates (alphavirus nsP3–FXR1) create actionable vulnerabilities—reinforcing a broader trend toward mapping “where the biology breaks” to guide intervention design.

---

Cardiometabolic risk biomarkers & lipid indices

Association of 14 triglyceride-glucose (TyG)-related indices with new-onset cardiovascular disease in middle-aged and older adults: evidence from the CHARLS and ELSA aging cohorts.

This longitudinal cohort study in 5,028 middle-aged and older adults from the CHARLS and ELSA aging cohorts evaluated whether single-time and cumulative-average triglyceride-glucose (TyG) indices predict new-onset cardiovascular disease (CVD). Multiple TyG-related indices and cumulative exposure improved risk stratification for incident CVD, supporting a clinically accessible TyG-based tool that accounts for longer-term insulin resistance/adiposity burden. These findings suggest that TyG-derived measures can be used for earlier identification of individuals at elevated CVD risk in aging populations.

Zhu ZL, Hu HF · Cardiovascular diabetology · (2026) · View on PubMed ↗ · Free PDF ↗

Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults: Standards of Care in Overweight and Obesity-2026.

This article summarizes the American Diabetes Association Obesity Association standards of care for screening, diagnosis, evaluation, and staging of overweight and obesity in adults (2026). It recommends annual screening for excess adiposity using BMI and provides diagnostic criteria using race- and ethnicity-specific BMI thresholds supplemented by waist circumference. The guideline is clinically significant because it standardizes how obesity is identified and staged to support earlier intervention and risk management.

BMJ open diabetes research & care · (2026) · View on PubMed ↗ · Free PDF ↗

Lipoprotein(a) and residual cardiovascular risk in statin-treated patients.

This analysis studied whether moderately elevated lipoprotein(a) [Lp(a)] levels below current clinical thresholds predict residual cardiovascular risk in statin-treated individuals, and whether effects differ by established ASCVD status. Using UK Biobank data (17,376 participants aged ≥45 years with established ASCVD or type 2 diabetes), it compared major adverse cardiovascular events (MACE: non-fatal MI, non-fatal stroke, or CV death) across Lp(a) tertiles (<12.5 vs >46.8 nmol/L). The clinical significance is that Lp(a) may identify ongoing risk even among statin-treated patients, potentially informing more refined risk stratification and future Lp(a)-lowering strategies.

Oftadeh SL, Pütz A, Jacobsen M et al. · European journal of preventive cardiology · (2026) · View on PubMed ↗

Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on the risk of venous thromboembolism in patients with obesity: a real-world cohort study.

This retrospective real-world cohort study used the TriNetX federated health research network to compare tirzepatide versus GLP-1 receptor agonists (GLP-1 RAs) for venous thromboembolism (VTE) outcomes in adults with obesity. Tirzepatide was associated with a different (comparative) risk of VTE relative to GLP-1 RAs, supporting a potential class-specific effect on DVT/PE risk in routine care. These findings are clinically relevant for selecting anti-obesity pharmacotherapy to mitigate thromboembolic risk, though causal inference remains limited by observational design.

Wu JY, Lee KW, Huang SC et al. · Frontiers in medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Non-HDL-to-HDL cholesterol ratio predicts incident T2DM and CHD in non-alcoholic fatty liver disease: evidence from a large clinical cohort and NHANES.

This study evaluated whether the non-HDL-to-HDL cholesterol ratio (NHHR) predicts incident type 2 diabetes mellitus (T2DM) and coronary heart disease (CHD) in non-alcoholic fatty liver disease (NAFLD) patients using a large retrospective clinical cohort (n=13,741; 2018–2025) and validation in NHANES (n=5,789; 1999–2018). It found that higher NHHR was associated with increased future risk of T2DM and CHD in NAFLD, with consistent results across the two cohorts. This is clinically significant because NHHR is a readily available lipid metric that could improve risk stratification for cardiometabolic complications in NAFLD.

Kou Y, Zhong Y, Zhang Q et al. · Frontiers in nutrition · (2026) · View on PubMed ↗ · Free PDF ↗

---

Atherosclerosis, vascular inflammation & lipid metabolism mechanisms

ACADM-mediated fatty acid β-oxidation pathway in atherosclerosis and abdominal aortic aneurysm.

This study investigated the ACADM-mediated fatty acid β-oxidation pathway in atherosclerosis versus abdominal aortic aneurysm using lipidomic profiling in mouse models and multiple human cohorts, combined with multi-omics integration, functional assays, and machine learning. The authors identified disease-specific lipid metabolic disturbances linked to ACADM-dependent β-oxidation signaling that differed between atherosclerosis and AAA. These results suggest ACADM-centered lipid metabolism as a mechanistic and potentially targetable pathway for distinguishing and treating these related vascular diseases.

Zhang H, Sun L, Xu T et al. · European heart journal · (2026) · View on PubMed ↗ · Free PDF ↗

AAV gene therapy for homozygous familial hypercholesterolemia: a phase 1 trial.

This phase 1 clinical trial evaluated an adeno-associated virus (AAV) gene therapy (NGGT006, AAV8 vector expressing codon-optimized LDLR cDNA) in patients with homozygous familial hypercholesterolemia (HoFH), most of whom have LDLR mutations. The therapy lowered LDL cholesterol (LDL-C) levels and was assessed for safety and efficacy in both preclinical LDLR-deficient models and HoFH patients. This provides early clinical evidence that liver-directed AAV-LDLR gene delivery may offer a durable treatment option for HoFH.

Zheng T, Gao G, Xu C et al. · Nature medicine · (2026) · View on PubMed ↗

New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering.

This review summarized emerging therapeutic targets aimed at lowering atherogenic ApoB-containing particles, emphasizing ApoB as the causal driver of atherosclerotic cardiovascular disease risk per particle. It discusses how ApoB-containing lipoproteins (including VLDL, LDL, chylomicron remnants, and Lp(a)) can be targeted beyond LDL cholesterol lowering, integrating genetic, epidemiologic, and randomized trial evidence. The scientific significance is a roadmap for next-generation lipid therapies that reduce atherogenic particle number by targeting ApoB biology.

Gaudet D, Larouche M, Raal FJ et al. · Circulation research · (2026) · 1 citations · View on PubMed ↗

Adipose Tissue Plasticity, Lipoprotein Metabolism, and Cardiovascular Risk: The Emerging Role of the GLP-1 Axis.

This review examined how adipose tissue plasticity and lipoprotein metabolism contribute to cardiovascular risk, focusing on the emerging role of the GLP-1 axis. It synthesizes evidence that GLP-1R agonists may improve cardiovascular risk through both weight-dependent and weight-independent mechanisms, particularly affecting postprandial lipoprotein metabolism and adipose tissue remodeling. The clinical significance is that GLP-1R-targeted therapies may confer cardioprotection via metabolic and adipose-lipid pathways beyond weight loss alone.

Repetti GG, Abel ED, Tontonoz P et al. · Circulation research · (2026) · 1 citations · View on PubMed ↗

Triglyceride-Rich Lipoprotein Metabolism and Cardiovascular Risk in Diabetes: Bedside to Bench to Bedside.

This review integrated clinical “bedside” observations with mechanistic “bench” data to explain how triglyceride-rich lipoproteins (TRLs)—VLDL and chylomicrons and their remnants—contribute to cardiovascular risk in diabetes. It argues that dysregulated TRL metabolism helps explain excess ASCVD risk in both type 1 and type 2 diabetes beyond traditional risk factors, using representative clinical cases linked to preclinical mechanistic insights. The significance is improved mechanistic understanding that could guide TRL- and remnant-targeted risk reduction strategies in diabetic patients.

Ginsberg HN, Bornfeldt KE · Circulation research · (2026) · 2 citations · View on PubMed ↗ · Free PDF ↗

A Dual-Phase Exosomal Nanotherapy Enhances Continual Efferocytosis by Coordinating Checkpoint Inhibition and Metabolic Reprogramming in Atherosclerosis.

This study developed a dual-phase engineered exosomal nanotherapy (Am@SExo) derived from macrophages to enhance continual efferocytosis in atherosclerosis by coordinating immune checkpoint inhibition and metabolic reprogramming. The key finding was that the therapy simultaneously countered the CD47–SIRPα checkpoint barrier to apoptotic cell recognition and promoted arginine metabolism (Arg1-mediated) to restore the metabolic capacity needed for ongoing efferocytosis. This is significant because it targets both recognition and metabolic processing defects that drive plaque necrotic core expansion and instability.

Zheng D, Cai S, Gao J et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

Cholesterol-Mediated Metabolic-mechanotransductive Crosstalk Orchestrates Castration Resistance in Prostate Cancer.

This mechanistic study investigated how cholesterol-mediated metabolic–mechanotransductive signaling drives castration resistance in prostate cancer (CRPC), focusing on full androgen deprivation (FAD) and the CH25H-dependent transformation of cancer-associated fibroblasts (CAFs) into myofibroblastic CAFs (myCAFs). FAD induced cholesterol metabolic rewiring in prostate cancer cells that promoted CH25H-dependent CAF phenotype switching, leading to increased matrix stiffness that activated unfolded protein response (UPR) and potentiated IRE1α kinase activity. These results identify a cholesterol–CH25H–matrix stiffness–IRE1α axis as a potential therapeutic target to prevent or reverse castration resistance.

Liu S, Xu C, Jiang J et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

Sphingolipid homeostasis and dysregulation in liver function and disease.

This 2026 Life Metabolism review summarized how sphingolipid homeostasis and dysregulation affect liver function and chronic liver diseases. It emphasizes that altered sphingolipid metabolism—particularly in metabolic dysfunction-associated steatohepatitis (MASH)—drives lipotoxic stress and lobule inflammation through remodeling of dihydroceramides/ceramides and increased neutral sphingomyelinase activity, alongside disrupted S1P signaling. The scientific significance lies in identifying sphingolipid pathways as mechanistic contributors and potential therapeutic targets across liver disease states.

Lan J, Pan Z, Dong W et al. · Life metabolism · (2026) · View on PubMed ↗ · Free PDF ↗

---

Kidney disease therapeutics & biomarkers (CKD/IgA nephropathy/renal immunology)

Finerenone in Persons with Chronic Kidney Disease without Diabetes.

This randomized, placebo-controlled trial studied finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in adults without diabetes who had chronic kidney disease (eGFR 25 to <90 ml/min/1.73 m²) and albuminuria (urinary albumin-to-creatinine ratio 200 to ≤3500) while receiving a renin-angiotensin system inhibitor. Finerenone (10 or 20 mg daily) was tested for its ability to improve kidney and cardiovascular outcomes compared with placebo in this non-diabetic CKD population. If effective, this would extend the clinical benefit of mineralocorticoid receptor blockade beyond type 2 diabetes to a broader CKD group defined by albuminuria.

Heerspink HJL, Neuen BL, Agarwal R et al. · The New England journal of medicine · (2026) · View on PubMed ↗

Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy.

In a phase 3 randomized trial, adults with primary membranous nephropathy were assigned to intravenous obinutuzumab (a type II anti-CD20 monoclonal antibody) or oral tacrolimus, with complete remission at week 104 as the primary endpoint. The study compared remission rates and safety profiles between B-cell depletion with obinutuzumab and calcineurin inhibition with tacrolimus. This head-to-head evidence is clinically significant for selecting first-line immunotherapy strategies in primary membranous nephropathy.

Fervenza FC, Hou FF, Hao CM et al. · The New England journal of medicine · (2026) · View on PubMed ↗

Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial.

This JAMA prespecified exploratory subgroup analysis evaluated finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in participants with chronic kidney disease due to investigator-reported glomerular diseases within a phase 3 randomized, double-blind, placebo-controlled trial across 24 countries/regions. The analysis assessed whether finerenone’s kidney-protective and safety effects observed in broader CKD populations extend to glomerular disease etiologies. Clinically, it informs whether mineralocorticoid receptor blockade should be prioritized for CKD patients defined by glomerular diagnoses rather than diabetes status alone.

Neuen BL, Perkovic V, Agarwal R et al. · JAMA · (2026) · View on PubMed ↗

Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure.

This secondary analysis of the CONFIDENCE trial assessed blood pressure effects of combined finerenone plus empagliflozin versus finerenone or empagliflozin monotherapy in people with chronic kidney disease and type 2 diabetes, stratified by baseline systolic blood pressure categories. The study evaluated systolic blood pressure changes and whether early (day 30) SBP reductions mediate urinary albumin-to-creatinine ratio improvements. These results are clinically relevant for understanding the safety and potential synergistic hemodynamic benefits of dual kidney-protective therapy in CKD with diabetes.

Agarwal R, Correa-Rotter R, Navaneethan SD et al. · Hypertension (Dallas, Tex. : 1979) · (2026) · View on PubMed ↗ · Free PDF ↗

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.

This randomized, double-blind, placebo-controlled phase 3 trial evaluated atrasentan, a selective endothelin A receptor antagonist, in adults with biopsy-proven IgA nephropathy receiving renin-angiotensin system inhibition to assess effects on 2.5-year eGFR decline. Atrasentan treatment was assessed for slowing eGFR deterioration after the prespecified week-36 proteinuria benefit reported earlier, extending efficacy evaluation to longer renal outcomes. If confirmed, these final 2.5-year results would support endothelin A blockade as a disease-modifying add-on therapy in IgA nephropathy beyond proteinuria reduction.

Heerspink HJL, Jardine MJ, Kohan DE et al. · Lancet (London, England) · (2026) · View on PubMed ↗

Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial.

The TRACK randomized clinical trial studied whether low-dose rivaroxaban versus placebo reduces adverse cardiovascular events in adults with advanced chronic kidney disease (CKD) (CKD stage 4 or 5 and dialysis-dependent kidney failure). The key finding, as framed by the trial objective, is that the study was designed to determine whether low-dose rivaroxaban lowers rates of fatal or nonfatal cardiovascular events compared with placebo in this high-risk population. If effective, this would directly inform antithrombotic management for advanced CKD patients, where the balance of benefit and bleeding risk is uncertain.

Badve SV, Perkovic V, Jha V et al. · JAMA · (2026) · 1 citations · View on PubMed ↗

Measured and Estimated Glomerular Filtration Rates and Risk of Adverse Health Outcomes.

This retrospective cohort study examined how measured glomerular filtration rate (mGFR) relates to adverse health outcomes and compared those associations with estimated GFR (eGFR) in 6,174 adults in Stockholm, Sweden. It used iohexol plasma clearance to obtain mGFR (primary exposure) and assessed outcomes including death and kidney/cardiovascular events, contrasting mGFR-based risk estimates with creatinine-based eGFR associations. The scientific significance is that it clarifies whether directly measured kidney function provides better prognostic information than eGFR in routine clinical risk prediction.

Fu EL, Créon A, Grams ME et al. · JAMA · (2026) · View on PubMed ↗

---

Cancer immunotherapy & immune modulation (checkpoint/cold reprogramming/immune microenvironment)

Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study.

The ARON-3 post hoc analysis compared doublet therapy (ADT plus androgen receptor pathway inhibitor, ARPI) versus triplet therapy (ADT plus ARPI plus docetaxel) in high-volume metastatic hormone-sensitive prostate cancer (mHSPC) with bone metastases, stratified by CHAARTED criteria (≤10 vs >10 bone metastases). The abstract indicates the study was designed to evaluate time-to-treatment failure and related outcomes for these regimens in this specific high-volume bone-metastatic population. This head-to-head evidence is intended to guide treatment selection for patients most likely to benefit from adding docetaxel to ADT+ARPI.

Mandel PC, Wenzel M, Gandur Quiroga MN et al. · European urology oncology · (2026) · View on PubMed ↗

Pathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimod.

This study examined how efgartigimod, an FcRn blocker, alters AChR-specific autoantibody pathogenic mechanisms and how those changes relate to clinical response in AChR autoantibody-positive generalized myasthenia gravis (MG). Using sera from 50 patients in the phase 3 ADAPT trial (efgartigimod vs placebo), it assessed complement activation, AChR internalisation, and ACh-binding site blockade and linked pathogenic antibody properties to treatment response. The findings support biomarker-driven understanding of why some MG patients respond better to efgartigimod, potentially improving patient selection and monitoring.

Khani-Habibabadi F, Verhamme FM, Moshir M et al. · Journal of neurology, neurosurgery, and psychiatry · (2026) · View on PubMed ↗

Diagnostic Value of Routine Delayed Pelvic Imaging for Patients with Biochemical Recurrence of Prostate Cancer Undergoing 68Ga-PSMA PET/CT.

This retrospective diagnostic study evaluated whether routine delayed pelvic imaging at 90 minutes improves detection of recurrence sites in prostate cancer biochemical recurrence (BCR) patients undergoing dual-phase 68Ga-PSMA PET/CT. Among 201 patients (median PSA 0.52 ng/mL), the key question was whether adding delayed pelvic acquisition increases diagnostic yield for small-volume disease not seen on standard timing. If effective, the approach could improve staging accuracy at low PSA levels and better guide salvage treatment decisions.

Jia KY, Kuten J, Jia HY et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · (2026) · View on PubMed ↗

Inhibition of histone demethylase LSD1 suppresses CD47 expression and enhances efficacy of CD47 blockade in breast cancer.

The research investigated whether inhibiting the histone demethylase LSD1 suppresses CD47 expression and thereby enhances the efficacy of CD47 blockade in triple-negative breast cancer (TNBC). Using in silico analyses, isogenic cell lines, conditional BRCA1 knockout models, and syngeneic mouse models, it tested the LSD1–CD47 signaling axis with assays including chromatin immunoprecipitation and protein ubiquitination, and evaluated immune effects relevant to macrophage phagocytosis. Scientifically, it suggests an epigenetic strategy (LSD1 inhibition) to overcome resistance to anti-CD47 immunotherapy by downregulating CD47.

Jiang F, Shen Y, Li B et al. · Journal for immunotherapy of cancer · (2026) · View on PubMed ↗ · Free PDF ↗

Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma.

This work investigated how hypoxia alters therapeutic response and resistance in metastatic clear cell renal cell carcinoma (ccRCC) using a transgenic ccRCC mouse model treated with VEGFR-TKIs, anti-PD-1, or the combination. The authors identified hypoxia-responsive SPP1+ tumor-associated macrophages (TAMs) that emerge during treatment and are linked to differential infiltration patterns and resistance mechanisms. These findings suggest that targeting hypoxia-driven TAM programs could improve durability of VEGFR-TKI and PD-1–based therapies in VHL-loss ccRCC.

Vuong L, Cornish AE, Pfeil J et al. · Cancer cell · (2026) · View on PubMed ↗ · Free PDF ↗

Frontline immunotherapy and immune cold reprogramming across molecular subtypes of advanced endometrial cancer.

This article reviewed frontline immunotherapy strategies and immune “cold reprogramming” across molecular subtypes of advanced endometrial cancer, focusing on mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) versus mismatch repair proficient (pMMR) disease. It highlights that PD-1/PD-L1 blockade moved to frontline standard for dMMR/MSI-H tumors, and that combining dostarlimab or pembrolizumab with platinum-based chemotherapy improved survival in untreated advanced disease based on RUBY and NRG-GY018. Clinically, it frames how molecular stratification guides checkpoint inhibitor selection and suggests approaches to convert pMMR tumors into more immunotherapy-responsive states.

Lin PH, Cheng SH, Raj EN et al. · Cancer letters · (2026) · View on PubMed ↗ · Free PDF ↗

Guanylyl Cyclase 2C-Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal Cancer.

This phase I clinical study tested guanylyl cyclase 2C (GUCY2C)-targeted chimeric antigen receptor (CAR) T cells in patients with metastatic colorectal cancer whose tumors were histologically confirmed to be GUCY2C-positive. The trial evaluated safety and preliminary efficacy using a 3+3 dose-escalation design across four dose levels (e.g., 3×10^8 to 12×10^8 CAR T cells) and a dose-expansion cohort. Scientifically and clinically, it explores a tissue-restricted antigen strategy for CAR T therapy in heavily pretreated metastatic CRC where later-line options are limited.

Qi C, Liu C, Gong J et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · (2026) · View on PubMed ↗

Reducing or omitting dexamethasone with NEPA and olanzapine for prevention of chemotherapy-induced nausea and vomiting in highly emetogenic chemotherapy: a randomized non-inferiority phase III trial.

This randomized phase III non-inferiority trial studied whether reducing or omitting dexamethasone (DEX) is feasible in adults receiving highly emetogenic chemotherapy (HEC) using NEPA (netupitant/palonosetron) plus olanzapine. Compared with standard 4-day DEX, DEX-sparing (6 mg on day 1 only) or DEX-free regimens were tested for non-inferior complete response (no emesis/no rescue) from 0–120 hours. If effective, this would reduce steroid exposure and potentially lessen toxicity and immunotherapy interference in HEC regimens.

Meng Y, Liu Y, Lin M et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · (2026) · View on PubMed ↗

Exercise training prior to and during cancer in mice preserves muscle mass, reduces tumour weight and suppresses molecular mediators of cachexia.

This preclinical study tested whether exercise training before and during cancer cachexia preserves muscle mass and suppresses cachexia mediators in male and female Balb/c mice. The key finding was that an 8-week voluntary progressive weighted wheel running (PoWeR) program initiated at 8 weeks of age and continued through colon-26 adenocarcinoma (C26) tumor development reduced tumor weight and mitigated cachexia-associated molecular changes while preserving muscle mass 25 days after tumor induction. This is significant because it supports a dual benefit of exercise—attenuating cachexia and limiting tumor burden—suggesting translational strategies for managing cancer cachexia.

Tsitkanou S, Koopmans PJ, Cabrera AR et al. · The Journal of physiology · (2026) · View on PubMed ↗ · Free PDF ↗

PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis.

This systematic review and meta-analysis compared overall survival and progression-free survival between PD-(L)1 inhibitor monotherapy and chemoimmunotherapy in treatment-naive advanced non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (≥50%). Adding chemotherapy to PD-(L)1 blockade improved outcomes versus PD-(L)1 monotherapy in this biomarker-defined population. The results inform first-line regimen selection for high–PD-L1 NSCLC by quantifying the survival impact of chemoimmunotherapy versus immunotherapy alone.

Di Federico A, Compagno S, Mantuano F et al. · JAMA oncology · (2026) · View on PubMed ↗

First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial.

This secondary analysis of the international, double-blind phase 3 ASTRUM-005 randomized clinical trial evaluated long-term efficacy, safety, patient-reported outcomes, and exploratory biomarkers for first-line serplulimab plus chemotherapy in extensive-stage small cell lung cancer (ES-SCLC). Extended follow-up confirmed sustained benefit and characterized the safety and patient-reported outcome profile of serplulimab-based treatment. The findings strengthen evidence for serplulimab as an immunotherapy component in ES-SCLC and support biomarker exploration for future personalization.

Liu J, Han L, Wu L et al. · JAMA oncology · (2026) · View on PubMed ↗

Metformin on the Presence of COVID-19 Symptoms 6 Months after Infection: The ACTIV-6 Randomized Clinical Trial.

The ACTIV-6 randomized clinical trial studied whether 14 days of metformin, compared with placebo, given to low-risk outpatient adults (≥30 years) with confirmed mild-to-moderate SARS-CoV-2 infection and ≥2 symptoms within 7 days of onset could prevent long COVID symptoms assessed at 6 months (day 180). The primary outcome results were not fully visible in the provided abstract text, but the trial design specifically targeted post-acute sequelae of SARS-CoV-2 or death (PASCD) by symptom attribution at day 180. If metformin reduces PASCD, it would support a repurposed, widely available drug strategy to prevent long COVID in early symptomatic infection.

Bramante CT, Stewart TG, Boulware DR et al. · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · (2026) · View on PubMed ↗

Plant-Derived Thylakoids Potentiate Copper-Mediated Multimodal Cell Death via Hypoxia Alleviation for Synergistic Antitumor Therapy.

This preclinical study investigated a multimodal antitumor platform (TC@UN/G) combining a copper-delivering metal-organic framework (UN), oxygen-generating plant-derived thylakoids (T) to alleviate tumor hypoxia, and a thermosensitive F127 hydrogel (G) for localized sustained release. The key finding is that peritumoral injection of TC@UN/G potentiated copper-mediated cuproptosis by alleviating HIF-1α-driven hypoxia-associated resistance, thereby enhancing synergistic tumor cell death. Scientifically and clinically, the approach suggests a way to overcome hypoxia-mediated failure of cuproptosis-based therapies in the tumor microenvironment.

Liu W, Wu J, Lan Z et al. · Small (Weinheim an der Bergstrasse, Germany) · (2026) · View on PubMed ↗

Tirzepatide in type 1 diabetes: beyond mere weight loss.

This narrative review studied the clinical potential of tirzepatide, a dual GLP-1R/GIPR agonist, specifically in type 1 diabetes mellitus (T1DM) beyond weight loss. It found that reported effects include reductions in glycated hemoglobin (HbA1c) by up to ~0.9% and body weight by up to ~23.4%, indicating meaningful glycemic and metabolic benefits in the T1DM context. Clinically, these data support further evaluation of tirzepatide as an adjunct or alternative strategy for T1DM patients, potentially addressing both glycemic control and weight-related comorbidity.

Panou T, Gouveri E, Popovic DS et al. · Expert review of clinical pharmacology · (2026) · View on PubMed ↗

Tumor Microenvironmental Regulation of CAR T-Cell Therapy in High Risk Medulloblastoma.

This preclinical study investigated how the tumor microenvironment regulates B7-H3-directed CAR T-cell therapy in high-risk group 3 medulloblastoma (G3MB), a pediatric brain tumor with poor immunotherapy durability. It focused on the dominant myeloid-mediated immunosuppressive TME and the Toll-like receptor 7/8 (TLR7/8) axis, proposing that integrating TLR7/8 agonists with CAR T cells could improve sustained CAR T function. The work is scientifically significant because it identifies a rational combination strategy to overcome TME-driven CAR T exhaustion in a difficult-to-treat pediatric cancer subtype.

Haydar D, Yaacoub S, Seblani M et al. · Research square · (2026) · View on PubMed ↗ · Free PDF ↗

An integrated analysis of SLC7A11 as a pan-cancer immunotherapeutic biomarker with experimental validation of its regulation by miR-148b-3p in breast cancer.

This study analyzed SLC7A11 as a pan-cancer immunotherapeutic biomarker using TCGA/GTEx datasets and evaluated experimental regulation by miR-148b-3p in triple-negative breast cancer. The key finding is that SLC7A11 expression associates with immunotherapy-related features across cancers and that miR-148b-3p can regulate SLC7A11 in breast cancer models. This supports SLC7A11/miR-148b-3p as a candidate biomarker axis for predicting immunotherapy response and for developing ferroptosis-linked therapeutic strategies.

Zhao S, Zheng M, Ma G et al. · Frontiers in immunology · (2026) · View on PubMed ↗ · Free PDF ↗

Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet).

This study reported the design and preliminary results of the randomized phase IIb TRIAD5-Plus trial in Lynch syndrome, testing multitargeted recombinant adenovirus 5 vaccines (Tri-Ad5: CEA, MUC1, brachyury) with or without the IL-15 receptor superagonist nogapendekin alfa inbakicept (NAI). The key finding from the preliminary phases is that the trial structure includes safety assessments of Tri-Ad5 alone versus Tri-Ad5 plus NAI, setting up a randomized controlled study to evaluate colorectal neoplasm prevention. This is clinically significant because it tests a cross-network immunoprevention strategy combining tumor antigen targeting with IL-15 pathway immune activation in a high-risk hereditary population.

Bansal A, Stoffel EM, Lim R et al. · Frontiers in immunology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Hematologic malignancies & transplant complications

Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

This EBMT Practice Harmonisation and Guidelines Committee review synthesized international evidence on donor cell-derived hematological neoplasms (DDHN) after allogeneic hematopoietic cell transplantation to propose pragmatic diagnostic criteria and downstream management guidance. The key finding is the absence of standardized diagnostic/therapeutic frameworks and the provision of a harmonized diagnostic framework incorporating molecular insights and donor outcomes. Clinically, this should improve recognition, classification, and treatment selection for this rare post-transplant complication across transplant centers.

Gurnari C, Armstrong C, Battipaglia G et al. · The Lancet. Haematology · (2026) · View on PubMed ↗

---

Solid tumor genomics, multi-omics & prognostic signatures

Clinical relevance of CA125 in low-grade serous ovarian cancer: a retrospective multi-center JAGO/NOGGO study.

This retrospective multi-center JAGO/NOGGO study evaluated whether serial serum CA125 measured at predefined clinical time points (at diagnosis, after debulking, during adjuvant therapy, during follow-up, and at recurrence) predicts progression and survival in patients with low-grade serous ovarian cancer treated at 9 tertiary centers in Germany and Austria between 2007 and 2023. Higher/abnormal CA125 trajectories at these time points were associated with worse outcomes and were assessed for their ability to detect recurrence. These findings support CA125 as a clinically actionable biomarker for risk stratification and recurrence monitoring in low-grade serous ovarian cancer.

Flethe C, Netkova-Heintzen M, Postl M et al. · International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · (2026) · View on PubMed ↗

Primary Cilium Forces Neuroendocrine Shift in Prostate Cancer through YAP1 Repression and Reduced Mitochondrial Activity.

This Theranostics study examined how primary cilia influence neuroendocrine (NE) prostate cancer biology by testing a mechanism involving YAP1 repression and reduced mitochondrial activity, using in vitro models, castration-resistant prostate cancer (CRPC) patient samples, and in vivo imaging/phenotyping. The authors found primary cilia in NE-like cells and CRPC tumor cells, associated with FDG-PET positivity and NE features, alongside reduced mitochondrial activity consistent with a metabolic shift. These findings suggest that ciliogenesis and YAP1-linked signaling may drive neuroendocrine progression and metabolic reprogramming in advanced prostate cancer.

Guo Y, Peng S, Jamet T et al. · Theranostics · (2026) · View on PubMed ↗ · Free PDF ↗

Comprehensive multi-omics analysis identifies cancer subtypes and prognostic signatures of hepatitis B virus-associated hepatocellular carcinoma.

This study performed comprehensive multi-omics analysis to classify hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC) and derive prognostic signatures using TCGA-LIHC data. Using the MOVICS package, it identified two cancer subtypes with distinct immune microenvironments and built a machine-learning prognostic signature (optimal RSF+Enet[alpha=0.2]) to predict outcomes. These results support refined HBV-HCC stratification and risk prediction that could inform personalized therapeutic decisions.

Wang R, Ren B, Zhang X et al. · NPJ precision oncology · (2026) · View on PubMed ↗ · Free PDF ↗

Integrative genomic analysis of 21 orofacial diseases identifies shared genetic architecture with systemic diseases.

This integrative genomic study analyzed 21 orofacial diseases in UK Biobank using genome-wide association, transcriptome-wide association, rare-variant association, and Mendelian randomization, then functionally tested prioritized genes. It identified 48 novel loci and prioritized 160 putative causal genes, including a synonymous ALDH1A2 variant linked to periodontitis where CRISPR-Cas9 editing demonstrated reduced translational efficiency and single-cell RNA-seq showed impaired retinoic acid signaling. The results connect specific genetic variation in ALDH1A2 to periodontitis biology and support shared causal pathways between orofacial and systemic diseases.

Nam K, Eom BS, Kim JY et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Pathogenesis of diffuse large B cell lymphoma proteogenotypes.

This study integrated proteomic, transcriptomic, and genomic data from 478 diffuse large B cell lymphoma (DLBCL) tumors to define disease-spanning proteogenotypes (PGs). It identified seven DLBCL proteogenotypes, with PG4 associated with poor outcome independent of established risk factors and enriched for BTG1 mutations that can activate MYC, alongside a dark-zone-related B-cell phenotype. Clinically, PG4 provides a proteogenomic stratifier that may refine prognosis and highlight actionable biology (BTG1/MYC axis) beyond conventional DLBCL subtyping.

Enssle JC, Häupl B, Qoku A et al. · Cancer cell · (2026) · View on PubMed ↗ · Free PDF ↗

TSPYL5 Promotes Triple-Negative Breast Cancer Metastasis by Antagonizing USP10-Mediated PTEN Stabilization to Unleash a ZEB1-Dependent EMT Program.

This study identified TSPYL5 as a driver of triple-negative breast cancer (TNBC) metastasis by showing it antagonizes USP10-mediated PTEN stabilization to unleash a ZEB1-dependent epithelial-to-mesenchymal transition (EMT) program. The key finding was that TSPYL5 amplification/overexpression predicts metastatic progression and that TSPYL5 defines a malignant, stem-like, genomically unstable subpopulation with pro-metastatic behavior, mechanistically linked to reduced PTEN stability and activation of ZEB1-driven EMT. Clinically, TSPYL5–USP10–PTEN–ZEB1 signaling emerges as a potential therapeutic axis to limit TNBC metastasis.

Shi J, Yi M, Xie S et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

Treatment Delays in Early Age-Onset Colorectal Cancer.

This retrospective, population-based cross-sectional study used Texas Cancer Registry data (2004-2019) to evaluate incidence and drivers of treatment delays in early age-onset colorectal cancer (EOCRC; diagnosis age <50). Patients with EOCRC experienced delays in initiation of definitive therapy, and the study identified targetable system and patient factors associated with delayed treatment. These findings highlight modifiable contributors to worse outcomes in EOCRC and support interventions to reduce time-to-treatment in younger patients.

Heslin RT, Whitham ZA, Pettigrew MF et al. · JAMA oncology · (2026) · View on PubMed ↗

Comparison of oncological outcomes between robotic and laparoscopic surgeries for gastric cancer: a multi-institutional cohort study in Japan.

This multi-institutional retrospective cohort study in Japan compared robotic gastrectomy (RG) versus laparoscopic gastrectomy (LG) for gastric cancer using 1:2 propensity score matching across 19 hospitals (2017-2020). The primary endpoint was 3-year relapse-free survival (RFS), with analyses designed to test non-inferiority of RG relative to LG. The study addresses whether robotic surgery provides oncologic safety comparable to standard laparoscopy in routine practice.

Fujita H, Nishigori T, Yamashita Y et al. · Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · (2026) · View on PubMed ↗

Reduced FBXO22 skews human trophoblast fate equilibrium toward syncytialization via polyubiquitinating the CoREST complex.

This molecular study examined how reduced FBXO22 affects human trophoblast stem cell fate, using recurrent pregnancy loss (RPL) patient tissue observations and experimental loss-of-function approaches. FBXO22 was enriched in cytotrophoblast nuclei and was reduced in early placental villi from RPL patients, and FBXO22 loss skewed trophoblast fate toward syncytialization via polyubiquitination of the CoREST complex. These findings implicate FBXO22–CoREST protein homeostasis as a regulator of trophoblast equilibrium and a potential contributor to pregnancy loss biology.

Li H, Song G, Zhou L et al. · Nucleic acids research · (2026) · View on PubMed ↗ · Free PDF ↗

Integrative omics identify NID2 as a therapeutic target linking depression and colorectal cancer in humans.

This iScience study used human integrative omics to identify nidogen-2 (NID2) as a shared therapeutic target linking major depression and colorectal cancer by analyzing a prospective colonoscopy cohort (n=2,857) and NHANES (n=37,597). Using two-sample Mendelian randomization and Bayesian colocalization integrating plasma protein quantitative trait loci (pQTL) with colorectal neoplasia GWAS data, it supported a depression-to-colorectal tumorigenesis connection mediated by NID2. The findings are clinically significant because they nominate NID2 for mechanistic follow-up and potential therapeutic targeting to address the depression–colorectal cancer comorbidity.

Huang L, Wang J, Tian H et al. · iScience · (2026) · View on PubMed ↗ · Free PDF ↗

Correlation of TTLL7-IT1/Hsa-miR-29c-3p/GLS with limited cutaneous systemic sclerosis and exploration of the underlying mechanisms.

This study investigated a ceRNA axis involving TTLL7-IT1 and hsa-miR-29c-3p and its association with GLS in limited cutaneous systemic sclerosis (lcSSc) using blood RNA sequencing and mechanistic validation. The key finding is that the TTLL7-IT1/hsa-miR-29c-3p/GLS regulatory relationship correlates with lcSSc and is explored as a mechanistic contributor via ceRNA network interactions. This suggests a potential biomarker and therapeutic target pathway for earlier diagnosis and intervention in lcSSc.

Dai X, Chen S, Zhu D et al. · Frontiers in immunology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Neurodegeneration, dementia & brain aging mechanisms

Human microglial transitions at the Aβ-tau inflection point associate with divergent pathways to dementia and resilience.

This human multi-omics study used spatial transcriptomics and single-nucleus RNA sequencing of superior frontal cortex tissue from octogenarians with or without dementia and cognitively intact centenarians to map microglial transitions at the amyloid-β (Aβ)–tau inflection point. It identified six spatial pathological domains and showed that the Aβ-to-tau transition is accompanied by divergent microglial state changes linked to either dementia progression or resilience. These results provide mechanistic biomarkers of how microglia respond to combined Aβ and tau pathology, informing stratified approaches to dementia risk.

Lu A, Chen WT, Dalby M et al. · Nature medicine · (2026) · View on PubMed ↗ · Free PDF ↗

GWAS on short tandem repeats identifies genetic mechanisms in Alzheimer’s disease.

This genome-wide association study (GWAS) analyzed short tandem repeats (STRs) in ~330,000 UK Biobank participants (including 3,287 Alzheimer’s disease cases and 47,048 AD-by-proxy cases) to identify STR loci influencing Alzheimer’s disease risk. It detected 15 independent genome-wide significant STR-associated loci, including both loci overlapping prior SNP findings and additional STR-specific signals. The study expands genetic architecture beyond SNPs and highlights STR variation as a contributor to Alzheimer’s disease susceptibility.

Gmelin D, Ohlei O, Aslam MM et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Memory reactivation underlies experience-dependent adaptive regulation of sleep.

This mouse study investigated how memory reactivation during sleep regulates sleep dynamics in an experience-dependent manner. Negative memory reactivation promoted arousal and sleep disturbance, whereas positive memory reactivation supported sleep stability, mediated by reactivation of experience-specific hippocampus–amygdala engram circuits; in chronic stress models, suppressing negative memory reactivation restored normal sleep. These findings establish a causal, circuit-level link between specific memory reactivation patterns and sleep regulation, suggesting targets for stress-related sleep disorders.

Yu M, Wang J, Zhai Z et al. · Science (New York, N.Y.) · (2026) · 1 citations · View on PubMed ↗

Cellular senescence in brain aging and neurodegeneration: from molecular mechanisms to translational opportunities.

This 2026 Frontiers in Cellular Neuroscience review synthesized evidence that cellular senescence contributes to brain aging and neurodegeneration, including Alzheimer’s disease (AD). It highlights accumulation of senescent glial cells (astrocytes, microglia, and oligodendrocyte progenitors) and emerging “neurescence” in post-mitotic neurons as drivers of neuroinflammation, impaired proteostasis, and synaptic dysfunction. The translational significance is that senescence pathways may represent actionable targets for developing interventions to slow or modify neurodegenerative progression.

Cantero-Fortiz Y, Butler C, Montalbán X et al. · Frontiers in cellular neuroscience · (2026) · View on PubMed ↗ · Free PDF ↗

Somatic mutations reveal the ontogeny of human microglia.

This study examined the ontogeny of human microglia by tracking marrow-derived cell infiltration into the brain using somatic mutations as clonal barcodes in 20 aged individuals. The key finding is that accumulated somatic mutations can reveal the developmental timing and extent of human microglial replacement by hematopoietic (marrow-derived) clones. This provides a scientific framework for quantifying human microglial lineage dynamics and for interpreting how peripheral immune contributions may shape neuroinflammatory disease.

Belk JA, Zhang Y, Shi Q et al. · bioRxiv : the preprint server for biology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Stroke & neuroprotection/neuroprosthetics

M2 microglia-derived migrasome-enriched extracellular vesicles restore mitochondrial homeostasis to orchestrate neurovascular unit recovery after ischemic stroke.

This preclinical study examined whether M2 microglia-derived migrasome-enriched extracellular vesicles (EVs) protect against ischemic stroke using OGD/R cell models and a mouse middle cerebral artery occlusion (MCAO) model. Migrasome-enriched EVs were internalized by microglia, astrocytes, neurons, and microvascular endothelial cells and promoted neurovascular unit recovery by restoring mitochondrial homeostasis and orchestrating anti-inflammatory repair programs. The work supports migrasome-enriched EVs as a potential cell-free neuroprotective strategy for ischemic stroke.

Zhang Y, Wu J, Liu L et al. · Journal of nanobiotechnology · (2026) · View on PubMed ↗ · Free PDF ↗

Spinal cord stimulation for upper limb motor function in people with chronic post-stroke hemiparesis: a feasibility trial.

This feasibility trial studied cervical epidural spinal cord stimulation (SCS) as a neuroprosthetic intervention in seven people with chronic post-stroke hemiparesis with upper-limb motor deficits. The intervention was reported as safe and feasible and produced preliminary functional improvements without requiring high-dose rehabilitation. If confirmed in larger trials, cervical SCS could become an adjunct therapy to improve arm/hand function after stroke.

de Freitas RM, Bhatia S, Sorensen E et al. · Nature medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Factors Associated with Poor Outcome after Successful Reperfusion in Patients with Large Infarct: A Post-Hoc Analysis of the TENSION Trial.

This post hoc analysis of the TENSION trial studied factors associated with poor functional outcome despite successful endovascular thrombectomy (EVT) reperfusion (TICI ≥2b) in patients with large infarct cores. Poor outcome was defined as modified Rankin Scale >3 at 12 months, and the analysis aimed to identify pre- and post-treatment variables linked to this outcome. Clinically, the work seeks to refine prognostication and highlight modifiable or measurable factors that influence recovery even after technically successful reperfusion.

Ciobanu-Caraus O, Heesen P, Fiehler J et al. · AJNR. American journal of neuroradiology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Neuroimmunology & microglia/innate immune regulation

Early-onset neuroinflammation drives neurodegeneration caused by lysosomal PI(3,5)P2 insufficiency.

This study used quantitative proteomics and transcriptomics in three mouse models carrying loss-of-function mutations in lysosomal PI(3,5)P2-generating PIKfyve complex subunits (Fig. 4) or Vac14 to define brain consequences from presymptomatic to end stages. The authors found profound neuroinflammation already at postnatal day 5, preceding significant neurodegeneration, in the setting of lysosomal PI(3,5)P2 insufficiency. These results identify early microglial/innate immune activation as a mechanistic driver of neurodegeneration in PI(3,5)P2 insufficiency disorders such as CMT4J and ALS, suggesting inflammation-targeted strategies may be beneficial early.

Wong B, Payne M, Silva A et al. · Neurobiology of disease · (2026) · View on PubMed ↗ · Free PDF ↗

Clonal lineage tracing of innate immune cells in human cancer.

This study developed a lineage-tracing method for innate immune cells in human cancer using somatic mitochondrial DNA (mtDNA) mutations combined with single-cell chromatin accessibility profiling. By jointly profiling mtDNA variants and single-cell chromatin accessibility, the authors reconstructed clonal dynamics across 218,715 cells from matched lung tumor, tissue, and blood samples. Scientifically, this enables clonal tracking of innate immune populations in native human tissues, which can clarify how innate lineages shape tumor evolution and immunotherapy responses.

Liu V, Sandor K, Yan PK et al. · Cancer cell · (2026) · View on PubMed ↗

Activity-dependent protein synthesis in neurons requires microglial-metabolic coupling.

This study examined how activity-dependent neuronal protein synthesis is supported by microglial metabolic coupling, using mammalian brain models with manipulations of microglia and metabolic signaling. It found that increased neuronal metabolic demand from a motor task stimulates microglia to secrete the hypoxia-responsive protein CYR61, which increases glucose transporter expression in brain vasculature and thereby fuels protein synthesis in active neurons. These results position microglia as a key upstream metabolic regulator of synaptic plasticity and memory, suggesting that disrupting the CYR61–vascular glucose pathway could modulate activity-dependent learning processes.

Adler D, Martín-Ávila A, Cheng E et al. · Cell metabolism · (2026) · View on PubMed ↗

Aging restricts maturation of CXCL13+ T follicular helper cells in human immunity.

This study investigated how human aging affects CXCL13+ T follicular helper (Tfh) cell maturation using human tonsil organoids, single-cell RNA sequencing, and CRISPR perturbations across donors of different ages. The key finding was that aging selectively restricts maturation of CXCL13+ Tfh cells, leading to weaker influenza-specific antibody responses driven by Tfh defects rather than B-cell defects. This is significant because it identifies a specific age-sensitive T-cell program that could be targeted to improve vaccine efficacy in older adults.

Bracey NA, Beppler C, Bilich T et al. · Cell reports · (2026) · View on PubMed ↗ · Free PDF ↗

---

Microbiome & host–pathogen interactions (bacteria/fungi/SCFAs/gut–liver axis)

Microbiota-derived short-chain fatty acids mediate Candida albicans gastrointestinal colonization resistance.

This study examined how microbiota-derived short-chain fatty acids (SCFAs) affect Candida albicans gastrointestinal colonization resistance in vivo and in mechanistic experiments. SCFAs directly inhibited C. albicans growth by inducing fungal metabolic reprogramming, impairing hexose uptake, and triggering intracellular acidification, and they enhanced colonization resistance in vivo when the gut microbiota was intact. These findings identify SCFAs as a mechanistic lever for preventing Candida overgrowth and subsequent disseminated fungal infection in immunocompromised hosts.

Mishra AA, Palmer SN, Zarek CM et al. · Cell host & microbe · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Gut pathobionts translocate into liver and reshape intrahepatic microbiome to facilitate hepatocellular carcinoma.

This study profiled matched gut and intrahepatic microbiomes in hepatocellular carcinoma (HCC) patients versus healthy subjects and tested whether gut pathobionts can translocate to the liver to promote tumor-associated changes. It found increased gut–liver microbiome similarity in HCC and a gut pathobiont-centered network, with stool transplantation from HCC patients into germ-free mice impairing gut barrier function and increasing bacterial load in liver, while tumor-region gut pathobionts correlated with host cytokine expression and oncogenic pathways. These findings support a gut–liver axis mechanism in HCC and suggest that targeting pathobiont translocation or downstream inflammatory/oncogenic signaling could be therapeutically relevant.

Liu W, Wang X, Zhang Y et al. · Cancer discovery · (2026) · View on PubMed ↗ · Free PDF ↗

---

Antiviral innate immunity & intracellular pathogen clearance

The antiphage mechanism of a widespread trypsin-MBL defense module.

This mechanistic microbiology study investigated a widespread trypsin–MBL (metallo-β-lactamase) defense module in diverse bacterial antiviral systems, focusing on the Hachiman-associated trypsin•HamAB–MBL pathway. It showed that infection-triggered sensing of foreign DNA activates trypsin-like activity by hydrolyzing ATP, which then cleaves autoinhibited MBL to release repression and deplete DNA. The findings clarify how protease–MBL modules execute antiphage defense and may guide engineering of programmable antimicrobial systems.

Huang P, Liu J, Guo L et al. · Nature chemical biology · (2026) · View on PubMed ↗

TRIM21 induces selective autophagy of viruses and bacteria.

This study investigated how the ubiquitin ligase TRIM21 can be harnessed to target pathogens for intracellular degradation using antibody-dependent capsid recognition in mammalian cells. The authors discovered an antimicrobial selective macroautophagy pathway termed “antibody-directed xenophagy (ADX)” that restricted structurally diverse pathogens including adenovirus and Salmonella. This provides a mechanistic framework for developing antibody-based intracellular clearance strategies that engage autophagy against otherwise resistant viruses and bacteria.

Rhinesmith T, Albecka A, Vaysburd M et al. · Molecular cell · (2026) · View on PubMed ↗ · Free PDF ↗

nsP3-FXR co-condensation enables alphavirus replication and reveals a targetable alphavirus vulnerability.

Using Venezuelan equine encephalitis virus (VEEV) as an alphavirus model, this study examined how non-structural protein 3 (nsP3) forms condensates via its alphavirus unique domain (AUD) and how these condensates depend on Fragile X-related protein 1 (FXR1). The key finding was that nsP3-AUD co-condensation with FXR1 enables viral replication by compartmentalizing replication complexes and bridging nsP3 to viral RNA through FXR1’s second Tudor domain. This reveals a targetable alphavirus vulnerability centered on nsP3–FXR1 condensate formation, offering a potential antiviral strategy.

Xie Y, Cao J, Yang X et al. · Cell reports · (2026) · View on PubMed ↗ · Free PDF ↗

HVEM-LIGHT signaling promotes antibody-dependent neutrophil FcγR-mediated trogocytosis against herpes simplex virus infection.

This study used HVEM ligand and conditional, cell-type-specific HVEM knockout mice plus in vitro mouse and human cytolytic assays to define the immune cells and signaling requirements for antibody-dependent cell-mediated killing (ADCK) of herpes simplex virus (HSV)-infected cells. The key finding was that ADCK is mediated primarily by neutrophils and requires HVEM expression/signaling in those effector cells. Clinically, it clarifies how HVEM-LIGHT pathways can shape FcγR-dependent neutrophil responses to HSV, informing vaccine and immunotherapy design.

Gromisch MS, Kuraoka M, Ware CF et al. · The Journal of clinical investigation · (2026) · View on PubMed ↗ · Free PDF ↗

Lost in translation: interferon-stimulated genes targeting flavivirus protein synthesis.

This mechanistic review studied how interferon-stimulated genes (ISGs) target flavivirus protein synthesis by disrupting host translation at multiple steps. It found that distinct ISG families inhibit translation initiation (e.g., PKR and IFIT proteins via initiation-factor or cap recognition interference) and elongation or ribosome engagement (e.g., SLFN11 and SAMD9L via codon/tRNA-dependent mechanisms), while others exclude viral RNAs from ribosomes or promote degradation (e.g., ZAP, SHFL, ISG20). Scientifically, mapping these ISG strategies clarifies why flaviviruses are vulnerable to innate immune pressure and can inform antiviral target discovery.

Cannac M, Zoladek J, Nisole S · Journal of virology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Immunology of allergy & type 2 inflammatory diseases

Efficacy and safety of acupuncture-related therapies in the treatment of allergic rhinitis: a systematic review and meta-analysis.

This systematic review and meta-analysis evaluated acupuncture-related therapies for allergic rhinitis by comparing three intervention categories: acupuncture plus medication, acupuncture alone, and conventional medication, with outcomes focused on efficacy and safety. The study synthesized available clinical evidence to determine whether acupuncture-related approaches improve allergic rhinitis outcomes relative to medication-based care and whether they add safety concerns. The results are intended to support evidence-based recommendations for integrating acupuncture into allergic rhinitis management.

Ma J, Peng M, Song YG et al. · Frontiers in medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Atopic dermatitis.

This article is a clinical science primer summarizing atopic dermatitis (AD) as the most common inflammatory skin disease and its burden, epidemiology, and comorbidities. It emphasizes that AD is driven largely by type 2 immune responses and is linked to conditions such as asthma, allergic rhinitis, food allergy, eosinophilic esophagitis, and other immune-mediated diseases. The review frames AD as a systemic, multi-comorbidity disorder and supports immune-pathway-based approaches for diagnosis and treatment.

Weidinger S, Aoiki V, Dhar S et al. · Nature reviews. Disease primers · (2026) · View on PubMed ↗

The Immune Architecture of Eosinophilic Esophagitis: Mechanisms, Therapeutic Targets, and Precision Management.

This narrative review studied the immune mechanisms driving eosinophilic esophagitis (EoE) and how they map to therapeutic targets and precision management strategies. It highlights a convergent type 2 immune network involving epithelial alarmins (TSLP, IL-33, IL-18), ILC2/Th2 activation, and effector interactions among eosinophils, mast cells, and fibroblasts that drive barrier disruption and fibrostenotic remodeling. Clinically, this synthesis supports more targeted, mechanism-based treatment selection and risk stratification in EoE beyond eosinophil counts alone.

Bertin L, Caldart F, Barchi A et al. · ImmunoTargets and therapy · (2026) · View on PubMed ↗ · Free PDF ↗

---

Autoimmunity & inflammatory disease therapeutics (IBD/RA/psoriasis/EoE/MCAS)

Combining Guselkumab with Upadacitinib Is Safe and Effective in the Treatment of Medically Complex Inflammatory Bowel Disease.

This real-world registry review assessed the safety and effectiveness of adding guselkumab (GUS) to upadacitinib (UPA) in medically complex adult inflammatory bowel disease (IBD). Dual-targeted therapy achieved clinical and biochemical remission endpoints while maintaining an acceptable adverse event profile in this complex population. The study supports feasibility of combining an IL-23 pathway inhibitor (guselkumab) with a JAK inhibitor (upadacitinib) for difficult-to-treat IBD cases.

Natt N, Choi D, Shafrir A et al. · Digestive diseases and sciences · (2026) · View on PubMed ↗ · Free PDF ↗

Skin Application of Inflammasome Inhibitor MCC950 Prevents Psoriasis-like Cutaneous Manifestations and Associated Systemic Inflammation.

This preclinical study tested whether topical administration of the selective NLRP3 inflammasome inhibitor MCC950 could prevent psoriasis-like cutaneous inflammation and associated systemic inflammation in an imiquimod-induced mouse model. MCC950 application inhibited NLRP3-driven inflammatory signaling, reducing both skin manifestations and systemic inflammatory readouts. The work supports topical NLRP3 inhibition as a strategy to blunt early psoriasis pathogenesis with potential systemic benefit.

Terranova C, Spitilli A, Camporeale A et al. · Inflammation · (2026) · View on PubMed ↗ · Free PDF ↗

Real-world efficacy and safety profile of four JAK inhibitors in rheumatoid arthritis: a French single-center observational study.

This retrospective single-center observational study evaluated real-world treatment maintenance, effectiveness, and safety of four JAK inhibitors—tofacitinib, baricitinib, upadacitinib, and filgotinib—in rheumatoid arthritis (RA) patients initiating first JAKi between April 2018 and November 2023 in France. Treatment maintenance and disease activity outcomes (DAS28-CRP and DAS28) were tracked over 6 and 12 months, and discontinuation reasons were analyzed in relation to prescribing changes after the October 2022 PRAC recommendations. The findings provide comparative real-world effectiveness and safety signals across JAK inhibitors and inform how regulatory guidance may influence clinical practice.

Abdellaoui S, Al Tabaa O, Hilliquin S et al. · Clinical rheumatology · (2026) · View on PubMed ↗ · Free PDF ↗

Cost-Effectiveness Analysis of Bimekizumab against Interleukin-23 Inhibitors in Patients with Plaque Psoriasis in Japan.

This cost-effectiveness analysis from a Japanese public healthcare payer perspective compared bimekizumab with IL-23 inhibitors for moderate-to-severe plaque psoriasis in Japan. The model estimated the incremental costs and health outcomes (QOL/utility-based measures) of bimekizumab versus IL-23 inhibitors and identified key parameters driving cost-effectiveness. The results help decision-makers evaluate value and accessibility of biologic options, particularly given bimekizumab’s dual IL-17A/IL-17F targeting.

Igarashi A, Shiraishi K, Saito S et al. · Dermatology and therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Progress in mast cell activation syndrome: the global consensus-2 diagnostic criteria at six years.

This article reviewed progress in mast cell activation syndrome (MCAS) and evaluated the impact of the global consensus-2 diagnostic criteria on diagnosis and treatment recognition worldwide. The key finding is that consensus-2, introduced in 2020, has increased recognition of MCAS and reduced underdiagnosis from overly restrictive criteria without evidence of resulting overdiagnosis. Clinically, broader adoption of consensus-2 should improve identification of this treatable disorder that is often misclassified as inflammatory syndromes or primary psychiatric conditions.

Afrin LB, Blitshteyn S, Bluestein LS et al. · Diagnosis (Berlin, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

Efficacy and safety of risankizumab in moderate-to-severe Crohn’s disease: a systematic review and meta-analysis.

This systematic review and meta-analysis of randomized controlled trials evaluated risankizumab, an IL-23 p19 inhibitor, for efficacy and safety in patients with moderate-to-severe Crohn’s disease (CD) across 7 RCTs totaling 4,411 participants. The pooled evidence supports risankizumab’s clinical and endoscopic benefits with an overall safety profile consistent with targeted IL-23 pathway inhibition. These results are important for treatment-refractory CD decision-making by clarifying expected outcomes of risankizumab in a defined patient population.

Nasim H, Siddiqui AH, Khan SJ et al. · Therapeutic advances in gastroenterology · (2026) · View on PubMed ↗ · Free PDF ↗

The UK vedolizumab real-life experience study in inflammatory bowel disease (VEST): patient characteristics, drug persistence and patient-centred outcomes.

This prospective UK multicenter observational cohort study (VEST) characterized real-world vedolizumab use in inflammatory bowel disease (IBD) across 22 centers, focusing on patient characteristics, drug persistence, and patient-centered outcomes. It reported how baseline disease activity and patient-reported measures (including IBD-Control Questionnaire and activity indices such as HBI/PMS) related to treatment persistence and response at week 14, alongside safety outcomes. The study is clinically significant because it translates vedolizumab trial endpoints into routine practice effectiveness and tolerability, informing expectations for persistence and patient-reported benefit.

Bodger K, Booker C, Taylor F et al. · Therapeutic advances in gastroenterology · (2026) · View on PubMed ↗ · Free PDF ↗

Mitochondrial dysfunction in sepsis-associated acute kidney injury: mechanisms and therapeutic potential.

This review studied mitochondrial dysfunction in sepsis-associated acute kidney injury (SA-AKI), focusing on mechanisms linking systemic inflammation and metabolic reprogramming to tubular epithelial injury. The key finding is that mitochondrial dysfunction acts as a central hub integrating pathogenic insults and driving renal functional decline. Scientifically and therapeutically, it frames mitochondrial pathways as actionable targets to reduce mortality and improve outcomes in critically ill adult patients with SA-AKI.

Wang C, Liu Q, Wang H et al. · Frontiers in immunology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Endocrine disruption & reproductive health

DEHP-induced male reproductive toxicity: Evidence from population studies, animal experiments, and multi-omics profiling.

This study evaluated associations between di(2-ethylhexyl) phthalate (DEHP) exposure and testosterone deficiency in adult men using NHANES 2013–2016 population data, alongside rat experiments and multi-omics profiling. DEHP exposure was linked to male reproductive toxicity features including altered sex hormones and testicular/epididymal pathology, with mechanistic signals involving oxidative stress and inflammation and identification of candidate molecular pathways/compounds (including CD6-related findings). These results support DEHP as an endocrine-disrupting chemical contributing to testosterone deficiency and male reproductive harm, informing risk assessment and potential therapeutic targeting.

Gong Z, Feng Q, Chen W et al. · Ecotoxicology and environmental safety · (2026) · View on PubMed ↗ · Free PDF ↗

---

Bioengineering, imaging, digital biomarkers & mechanistic tools

The NTR/prodrug revolution: Tools for controlling cell loss and regeneration.

This eLife review studied the NTR/prodrug chemogenetic system (nitroreductase enzymes such as bacterial nfsB with corresponding prodrugs) as a tool for spatiotemporal control of targeted cell ablation and regeneration, with emphasis on its development from transgenic mouse models to extensively optimized zebrafish applications. The key finding is that the NTR/prodrug approach provides precise, reversible-like control over cell loss by converting inert prodrugs into cytotoxic agents in NTR-expressing cells. Scientifically, it consolidates practical guidance and future strategies for building versatile ablation models for developmental biology and disease modeling.

Kim GJ, Parsons M · eLife · (2026) · View on PubMed ↗ · Free PDF ↗

The molecular architecture of tunneling nanotubes.

This bioRxiv preprint studied tunneling nanotubes (TNTs) by developing two complementary experimental systems to characterize TNT formation and function, addressing limitations of light microscopy and lack of morphological criteria. The authors used stimulation with the pseudorabies viral kinase US3 to induce TNT formation and to probe TNT-mediated transfer processes. Establishing robust TNT criteria and assays is scientifically significant for clarifying TNT roles in tumor biology, viral spread, and chemotherapy resistance.

Karasmanis EP, Chen S, Shaikh F et al. · bioRxiv : the preprint server for biology · (2026) · View on PubMed ↗ · Free PDF ↗

Antioxidant lipid nanoparticles enhance mRNA stability for regeneration therapy and gene editing.

This preclinical study developed antioxidant lipid nanoparticles (LNPs) to protect therapeutic mRNA from oxidative degradation and improve mRNA stability for regeneration therapy and gene editing. It designed a library of antioxidant ionizable lipids and identified a lead LNP formulation containing a 4-hydroxyphenyl-modified antioxidant lipid that scavenged reactive species and preserved mRNA integrity under oxidative stress. The approach provides a generalizable LNP design strategy to enhance mRNA performance in challenging oxidative environments.

Li B, Zhao M, Yang B et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Structural dynamics of kappa opioid receptor interactions with β-arrestin 1.

The study used cryogenic electron microscopy to determine the structural dynamics of the kappa opioid receptor (KOR) bound to β-arrestin 1 (βarr1), focusing on phosphorylation and lipid interactions. The KOR–βarr1 complex was resolved at 2.60 Å and showed multiple phosphorylation sites plus a phospholipid-binding site that specifically enhances β-arrestin recruitment, with a core interaction pattern distinct from other GPCR–βarr1 complexes. These findings clarify how KOR phosphorylation and membrane lipid engagement tune arrestin-biased signaling, informing rational design of next-generation kappa opioid therapeutics.

Han J, Fine EJ, Jiang Q et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Expert consensus on treatment of condylar hyperplasia and secondary dento-maxillofacial deformities.

This article provides an expert consensus framework for treating condylar hyperplasia (CH) and secondary dento-maxillofacial deformities, integrating disease activity, severity, and malocclusion into individualized planning. It recommends combined temporomandibular joint (TMJ)–orthognathic approaches and outlines surgical options including hyperplastic condylar resection, orthognathic surgery, facial contour surgery, and orthodontic treatment. Clinically, the consensus aims to standardize decision-making to restore TMJ function, occlusion, and facial harmony in CH patients.

Bi R, Abotaleb BM, Bai X et al. · International journal of oral science · (2026) · View on PubMed ↗ · Free PDF ↗

Global burden of drug-resistant tuberculosis in children: A systematic analysis for the Global Burden of Disease Study.

This systematic analysis quantified the global burden of drug-resistant tuberculosis in children by using the Global Burden of Disease Study 2021 database for MDR/RR-TB and XDR-TB. It estimated incident cases, deaths, and age-standardized incidence and mortality rates for children aged 0–14 years, stratifying by age, sex, region/country, and HIV/AIDS status and assessing trends with joinpoint regression. The results are important for public health planning by identifying where and how rapidly childhood DR-TB burden is changing worldwide.

Liu X, Mijiti P, Xia L et al. · The European respiratory journal · (2026) · View on PubMed ↗

Single-cell mapping of regulatory DNA-protein interactions.

This study developed D&D-seq, a single-cell immuno-tethering technique to map DNA–protein interactions in single cells, including weak or transient transcription factor binding. By coupling a nanobody to a cytosine base editor, D&D-seq detects protein-bound genomic sites via targeted cytosine-to-uracil editing, enabling single-cell resolution of regulatory interactions. This advances mechanistic genomics by making TF–DNA interaction mapping feasible at the single-cell level rather than relying on bulk or affinity-limited assays.

Chi WY, Yoon SH, Goksel E et al. · Cell · (2026) · View on PubMed ↗

Deep learning of functional perturbations from condensate morphology.

This study introduced Deep-Phase, a neural-network framework that infers functional perturbations from biomolecular condensate morphology changes measured by microscopy after pharmacological interventions. The key finding is that Deep-Phase can quantify time- and concentration-dependent structural perturbations in multiphase condensates (including the nucleolus) and link them to drug potencies for inhibitors of ribosomal biogenesis-related processes (ribosomal R). This provides a scalable, image-based way to connect mesoscale condensate organization to biochemical target engagement and drug response.

Donlic A, Comi TJ, Quinodoz SA et al. · Cell · (2026) · View on PubMed ↗ · Free PDF ↗

Plasma signals of lung tumor promotion for molecular cancer prevention.

This study used machine learning to identify and validate a plasma protein signature predicting lung cancer risk more than 5 years before diagnosis. The authors found a 14-protein signature elevated in current smokers and individuals exposed to particulate matter, linked to lung myeloid and alveolar cells, and validated across eight cohorts. Scientifically and clinically, this could enable earlier molecular cancer prevention trial enrichment by selecting higher-risk individuals using blood-based biomarkers.

Pandya T, Zagorulya M, Leung MM et al. · Cell · (2026) · View on PubMed ↗ · Free PDF ↗

Distinct prion conformers from brain and peripheral tissues of gene-targeted mice produce convergent CWD strain properties.

This study compared prion strain properties generated by gene-targeted mouse models using prion protein (PrP) conformers derived from brain versus peripheral tissues (e.g., skeletal muscle and lymphoreticular tissues) in the context of chronic wasting disease (CWD)-relevant biology. The key finding was that distinct prion conformers from brain and peripheral tissues converged on CWD-like strain properties, indicating that peripheral replication can yield strain characteristics similar to CNS-derived strains. This supports a mechanistic link between tissue-specific prion conformations and the high peripheral infectivity that drives CWD transmission in cervids.

DeFranco JP, Atkinson ZN, Crowell J et al. · PLoS pathogens · (2026) · View on PubMed ↗ · Free PDF ↗

Electrolyte imbalance in Asphyxiated term neonates: Incidence, predictors, and outcomes from a prospective cohort study in Northern Uganda.

This prospective cohort study enrolled term neonates with birth asphyxia in Lira Regional Referral Hospital, Northern Uganda, to determine the incidence, predictors, and early clinical outcomes of electrolyte imbalance. The key finding was that electrolyte abnormalities occurred frequently after asphyxia and were associated with worse early outcomes, with specific clinical factors predicting which neonates developed imbalances. Clinically, the results argue for early electrolyte monitoring and targeted correction in asphyxiated term neonates to improve survival and reduce short-term morbidity.

Yusuf B, Ediamu T, Odoch S et al. · PloS one · (2026) · View on PubMed ↗ · Free PDF ↗

Higher versus Routine Intraoperative Blood Pressure Targets in Noncardiac Surgery: A Systematic Review and Meta-analysis with Trial Sequential Analysis of Randomized Trials.

This systematic review and meta-analysis with trial sequential analysis synthesized randomized trials in adults undergoing elective noncardiac surgery comparing higher intraoperative mean arterial pressure (MAP) targets versus routine blood pressure management. The key finding was that targeting higher MAP thresholds (either fixed or individualized to baseline) did not clearly demonstrate improved postoperative outcomes compared with guideline-concordant routine targets. Scientifically and clinically, the evidence suggests that simply raising intraoperative MAP above standard recommendations may not confer additional benefit, informing future perioperative blood pressure guideline refinement.

Chiou K, Vikram S, Rowshan K et al. · Anesthesiology · (2026) · View on PubMed ↗

A conserved antioxidant defense at the endoplasmic reticulum membrane.

This study combined AlphaFold2 predictions with functional genetic screens in Caenorhabditis elegans to identify an evolutionarily conserved endoplasmic reticulum (ER) protein involved in antioxidant defense, then validated relevance in humans. The key finding was that ERGU-1 (with a human homolog TMEM161B) localizes to the ER membrane and is required to limit ER-generated hydrogen peroxide (H2O2), with ERGU-1 deletion triggering NRF2/SKN-1-dependent antioxidant gene expression and impairing reproduction and behavioral responses to H2O2. Scientifically, it defines a conserved ER membrane antioxidant defense pathway that protects proteostasis and organismal fitness.

Ji Z, de Belly H, Pandey T et al. · Cell reports · (2026) · View on PubMed ↗ · Free PDF ↗

Zebrafish knock-in lines enabling live visualization of extracellular matrix dynamics during development and regeneration.

This study created zebrafish knock-in lines to visualize extracellular matrix (ECM) dynamics during development and regeneration by tagging endogenous ECM proteins. Using C-terminus in-fusion genome editing, the authors generated lines for Lamc1 (laminin gamma 1), Col1a2 (collagen type I alpha 2), and Tgfbi, and used fluorescence recovery after photobleaching (FRAP) to assess protein stability (e.g., Lamc1 stability in fin). The scientific significance is that these live imaging tools enable direct observation of ECM composition and behavior in vivo, advancing mechanistic understanding of tissue regeneration.

Shen J, Jayadev R, Gillotay P et al. · Development (Cambridge, England) · (2026) · View on PubMed ↗

A framework of digital biomarkers for neurodegenerative diseases.

This 2026 Nature Reviews Bioengineering article reviewed how digital biomarkers (DBMs) derived from smartphones, wearables, and ambient sensors can be standardized and used for neurodegenerative disease monitoring. It concludes that DBMs provide continuous, real-time, context-rich measurements that complement conventional biomarkers and can help screen candidates for invasive testing and enable remote/personalized assessment. The framework is scientifically significant because it supports scalable, harmonized DBM development and validation for neurodegenerative diagnosis, prognosis, and clinical trials.

Nerrise F, Schütz N, Zhao Q et al. · Nature reviews bioengineering · (2026) · View on PubMed ↗

A generalizable system for antigenic peptide targeting across HLA-I allotypes.

This bioRxiv preprint describes a generalizable framework for designing antigenic peptide targeting across HLA-I allotypes by combining PepPred peptide conformational prediction with a cross-HLA binding protein engineering system (TRACeR-I1) to generate xTRACeRs. The approach addresses HLA polymorphism barriers by engineering binders that can recognize peptide antigens across divergent HLA-I backgrounds. This is significant for immunotherapy development because it aims to expand therapeutic coverage beyond single-HLA constraints, improving applicability across genetically diverse patients.

Blackson W, Small EL, Sun SM et al. · bioRxiv : the preprint server for biology · (2026) · View on PubMed ↗ · Free PDF ↗

Piezo3 is a novel mechanosensitive Piezo ion channel in vertebrates.

This study investigated the evolutionary origin and function of a newly identified vertebrate mechanosensitive ion channel, piezo3, alongside the known Piezo1 and Piezo2 channels. The authors report identification of Piezo3 as a novel Piezo family paralog and propose it as an additional mechanosensing component in vertebrates. These findings expand the mechanotransduction gene repertoire beyond Piezo1/2 and suggest new targets for understanding mechanosensory physiology and related disease mechanisms.

Dong Z, Wang D, Wang B et al. · bioRxiv : the preprint server for biology · (2026) · View on PubMed ↗ · Free PDF ↗

Structure of the human HIRA histone chaperone with a nucleosome suggests a stepwise nucleosome assembly mechanism.

This study determined the structure of the human HIRA histone chaperone bound to a nucleosome to infer how HIRA mediates replication-independent deposition of the histone variant H3.3. The key finding is that the nucleosome-bound structure supports a stepwise nucleosome assembly mechanism orchestrated by HIRA’s three-subunit architecture. This structural mechanism clarifies how active chromatin is reassembled after transcription and informs how HIRA disruption could contribute to genome integrity defects and cellular senescence.

Tian W, Chen S, Yao L et al. · bioRxiv : the preprint server for biology · (2026) · View on PubMed ↗ · Free PDF ↗

---

---

Generated automatically on June 06, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.